FK949E

Phase 3Small molecule

Astellas

FK949E is one of 96 small molecule programs targeting Major Depressive Episode. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive EpisodeActive, not recruiting

Major Depressive DisorderActive, not recruiting

Bipolar DisorderActive, not recruiting

Major Depressive EpisodePhase 2/Phase 3

Active, not recruiting

Major Depressive DisorderPhase 1

Active, not recruiting

Bipolar DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

5 2

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 3

4 3

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 4

Fetzima

AbbVie

Phase 3

9 5

Lisdexamfetamine Dimesylate

Takeda

Phase 3

1 6

ALKS 37

AAlkermes, Inc.

Phase 3

6 7

Desvenlafaxine SR

Pfizer

Phase 3

13 8

Brenipatide

Eli Lilly

Phase 3

—9

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

2 10

AXS-05

AAxsome Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depressive Disorder4 trials

Oral Multiple-dose Study in Patients With Major Depressive Disorder

Completed· Astellas logo

Astellas·Phase 1·NCT01924520·32 enrolled

Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder

Completed· Astellas logo

Astellas·Phase 1·NCT01919008·16 enrolled

Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder

Completed· Astellas logo

Astellas·Phase 1·NCT01903200·16 enrolled

Show 1 more trial

Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder

Completed· Astellas logo

Astellas·Phase 1·NCT01871974·16 enrolled

Major Depressive Episode2 trials

Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

Completed· Astellas logo

Astellas·Phase 3·NCT02362412·22 enrolled

A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

Completed· Astellas logo

Astellas·Phase 2/3·NCT01725308·431 enrolled

Concentration2 trials

Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

Completed· Astellas logo

Astellas·Phase 1·NCT01871987·24 enrolled

Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers

Completed· Astellas logo

Astellas·Phase 1·NCT01908296·24 enrolled

Bipolar Disorder1 trial

Long-term Study of FK949E in Elderly Bipolar Disorder Patients

Completed· Astellas logo

Astellas·Phase 3·NCT01737268·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for FK949E. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FK949E compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FK949E. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Astellas

FK949E

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depressive Disorder4 trials

Major Depressive Episode2 trials

Concentration2 trials

Bipolar Disorder1 trial

References

Drug Info

Quick Facts

Related News